CARIBOU BIOSCIENCES, INC.

Profile

Company Names

CARIBOU BIOSCIENCES, INC.

Addresses

2929 7TH STREET, SUITE 105, BERKELEY, CA 94710

2929 7TH STREET, STE 120, BERKELEY, CA 94710

Phone Numbers

510-982-6030

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2011

State Incorporated:

DELAWARE

Total Amount Raised:

$141,008,823.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2021-03-02 
$114,999,613.00 
$114,999,613.00 
$0.00 
Equity 
2
2016-05-12 
$14,459,306.00 
$30,070,244.00 
$15,610,938.00 
Equity 
1
2014-09-11 
$11,549,904.00 
$11,549,904.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
PHILIP 
 
AUSTIN 
DIRECTOR
CARIBOU BIOSCIENCES, INC.   |  VESTARON CORP   |  AGRIMETIS, LLC   |  ENKO CHEM, INC.   |  ZEBIAI THERAPEUTICS, INC.   |  INVETX, INC.   |  ANIMOL DISCOVERY, INC.   |  BERKELEY FERMENTATION SCIENCE INC.
RODOLPHE 
 
BARRANGOU 
DIRECTOR
CARIBOU BIOSCIENCES, INC.   |  ANCILIA BIOSCIENCES, INC.   |  HOOFPRINT BIOME, INC.
RACHEL 
 
HAURWITZ 
EXECUTIVE OFFICER, DIRECTOR
CARIBOU BIOSCIENCES, INC.   |  INTELLIA THERAPEUTICS, INC.
RACHEL 
E. 
HAURWITZ 
EXECUTIVE OFFICER, DIRECTOR
CARIBOU BIOSCIENCES, INC.
STEVEN 
B. 
KANNER 
EXECUTIVE OFFICER
CARIBOU BIOSCIENCES, INC.
UN 
 
KWON-CASADO 
EXECUTIVE OFFICER
CARIBOU BIOSCIENCES, INC.
JEFFREY 
 
LONG-MCGIE 
DIRECTOR
CARIBOU BIOSCIENCES, INC.   |  HINGE BIO, INC.
ANDREW 
 
MAY 
EXECUTIVE OFFICER
CARIBOU BIOSCIENCES, INC.   |  TRUXTON CAPITAL I, LLC   |  ASCEND GENE + CELL THERAPIES LTD.
ANDREW 
P. 
MAY 
EXECUTIVE OFFICER
CARIBOU BIOSCIENCES, INC.
BARBARA 
G. 
MCCLUNG 
EXECUTIVE OFFICER
INTARCIA THERAPEUTICS, INC   |  CARIBOU BIOSCIENCES, INC.
JASON 
 
O-BYRNE 
EXECUTIVE OFFICER
CARIBOU BIOSCIENCES, INC.
SANTHOSH 
 
PALANI 
DIRECTOR
CARIBOU BIOSCIENCES, INC.   |  METAGENOMI TECHNOLOGIES, LLC
JENNY 
 
ROOKE 
DIRECTOR
CARIBOU BIOSCIENCES, INC.   |  ADARZA BIOSYSTEMS, INC.   |  INTABIO, INC.   |  GENOA VENTURES FUND I, LP   |  VENN BIOSCIENCES CORP   |  GENOA OPPORTUNITY SPV I, LLC   |  GENOA OPPORTUNITY SPV II, LLC   |  GENOA OPPORTUNITY SPV III, LLC   |  GENOA OPPORTUNITY SPV V, LLC   |  BRIGHTSPEC, INC.
NATALIE 
R. 
SACKS 
DIRECTOR
HARPOON THERAPEUTICS, INC.   |  CARIBOU BIOSCIENCES, INC.
ROBERT 
 
WEISSKOFF 
DIRECTOR
TETRAPHASE PHARMACEUTICALS INC   |  ACCURI CYTOMETERS INC   |  TRANSAVE INC   |  IKANO THERAPEUTICS INC.   |  ACORN CARDIOVASCULAR INC   |  VIEWRAY INC   |  BIOCONNECT SYSTEMS INC   |  AMPHORA MEDICAL, INC.   |  CARIBOU BIOSCIENCES, INC.   |  IOWA APPROACH, INC.   |  ZENFLOW, INC.   |  TEMPEST THERAPEUTICS, INC.   |  FARAPULSE, INC.   |  CHECKMATE PHARMACEUTICALS, INC.   |  AFFINIA THERAPEUTICS INC.   |  XILIO THERAPEUTICS, INC.   |  RARECYTE, INC.   |  SHOUTI INC.   |  BASECAMP BIO INC.   |  ADELA, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2021-03-05
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2021-03-02 
2016-05-25
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2016-05-12 
2015-03-24
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-09-11 
2014-09-23
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-09-11 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
SVB LEERINK LLC
39011